News: hRPCs for Retinitis Pigmentosa

Priority focus now on Exosome drug delivery technology & Partnerships Ophthalmology assets to be out-licensed

18 January 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell and Exosomes Technologies, announces a strategic update following a review of the latest data from the hRPC (human retinal progenitor cells) Phase 2a clinical trial for retinitis pigmentosa (RP) and an assessment of the commercial potential for its Exosome technology.

Read more…

30 November 2021: ReNeuron Group plc (AIM: RENE), a UK based leader in Stem Cell and Exosome Technologies, announces its interim results for the six months ended 30 September 2021.

Read more…

Oxford University Hospitals NHS Foundation Trust activated as ReNeuron’s first UK study site

18 October 2021: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides a further update on the progress of its Phase 2a clinical evaluations for the treatment of retinitis pigmentosa (‘RP’), an inherited, degenerative eye disease.

Read more…

01 October 2021: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides an update on the Company’s Phase 2a clinical evaluations for the treatment of retinitis pigmentosa (‘RP’), an inherited, degenerative eye disease.

Read more…

17 December 2020: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that the US Patent and Trademark Office (USPTO) has completed its examination of patent application 15/613,030, entitled: “Low oxygen culture conditions for maintaining retinal progenitor cell multipotency”, and has issued a notification of allowance for the issuance of a patent.

Read more…

10 September 2020: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, is pleased to provide a trading update ahead of today’s Annual General Meeting (“AGM”).

Read more…

31 July 2020: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that the US Patent and Trademark office (USPTO) has completed its examination of the Company’s patent application (14/379,239), entitled: “Phenotype profile of human retinal progenitor cells” and has issued a notification of allowance for the issuance of a patent.

Read more…

Further long-term data demonstrate continuing, clinically meaningful efficacy at all time-points measured out to 18 months post-treatment

29 June 2020: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, is pleased to announce further positive long-term data from the ongoing Phase 2a clinical trial of its hRPC stem cell therapy candidate in retinitis pigmentosa (RP).  RP is a group of hereditary diseases of the eye that lead to progressive loss of sight and ultimately blindness.

Read more…

17 June 2020: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, provides the following update on its cell-based therapy programmes.

Read more…